Vaccine (Live attenuated vaccine) · Immune activation · developed by Sanofi Vaccines US
YF-VAX is a live, attenuated viral vaccine against yellow fever, a disease endemic to parts of Africa and South America. It is given as a subcutaneous injection of powder and diluent for suspension, and is studied for yellow fever immunization.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07103148 | Phase 3 | Yellow Fever Immunization | Active not recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Yellow Fever Immunization
Updated Nov 8, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →